Policy options for pharmaceutical pricing and purchasing: issues for low-and middle-income countries

TA Nguyen, R Knight, EE Roughead… - Health Policy and …, 2015 - academic.oup.com
Pharmaceutical expenditure is rising globally. Most high-income countries have exercised
pricing or purchasing strategies to address this pressure. Low-and middle-income countries …

Doctor–patient communication, health-related beliefs, and adherence in glaucoma: results from the glaucoma adherence and persistency study

DS Friedman, SR Hahn, L Gelb, J Tan, SN Shah… - Ophthalmology, 2008 - Elsevier
OBJECTIVE: To use multiple data sources to determine drivers of patient adherence to
topical ocular hypotensive therapy. DESIGN: Retrospective database and chart reviews in …

Financial and family burden associated with cancer treatment in Ontario, Canada

CJ Longo, M Fitch, RB Deber, AP Williams - Supportive Care in Cancer, 2006 - Springer
Goals of work To determine the financial and family resources burden associated with the
treatment of cancer. A questionnaire was developed to determine the direct monthly “out-of …

The impact of co‐payment increases on dispensings of government‐subsidised medicines in Australia

A Hynd, EE Roughead, DB Preen… - … and drug safety, 2008 - Wiley Online Library
Purpose Patient co‐payments for medicines subsidised under the Australian
Pharmaceutical Benefits Scheme (PBS) increased by 24% in January 2005. We investigated …

Affordability of medicines and patients' cost-reducing behaviour: empirical evidence based on SUR estimates from Italy and the UK

V Atella, E Schafheutle, P Noyce, K Hassell - Applied health economics …, 2005 - Springer
Introduction Studies have demonstrated that co-payments on medication reduce the
consumption of both non-essential and essential drugs, and that the latter can lead to worse …

How much do we spend on prescription medicines? Out-of-pocket costs for patients in Australia and other OECD countries

A Kemp, DB Preen, J Glover, J Semmens… - Australian Health …, 2011 - CSIRO Publishing
Objectives. To determine changes in out-of-pocket expenditure on prescription medicines for
Australian patients, and how patient expenditure compares with other Organisation for …

Impact of cost of medicines for chronic conditions on low income households in Australia

A Kemp, DB Preen, J Glover… - Journal of health …, 2013 - journals.sagepub.com
Objectives: To determine the cost of medicines for selected chronic illnesses and the
proportion of discretionary income this would potentially displace for households with …

Australian population trends and disparities in cholinesterase inhibitor use, 2003 to 2010

RR Zilkens, J Duke, B Horner, JB Semmens… - Alzheimer's & …, 2014 - Elsevier
Abstract Background The Australian Pharmaceutical Benefits Scheme (PBS) first subsidized
cholinesterase inhibitors (CEIs) for Alzheimer's disease in 2001, introducing a novel therapy …

Costs of medicines and health care: a concern for Australian women across the ages

EJ Walkom, D Loxton, J Robertson - BMC Health Services Research, 2013 - Springer
Abstract Background Evidence from Australia and other countries suggests that some
individuals struggle to meet the costs of their health care, including medicines, despite the …

Is 50 cent the price of the optimal copayment?-a qualitative study of patient opinions and attitudes in response to a 50 cent charge on prescription drugs in a publicly …

SJ Sinnott, M Guinane, H Whelton, S Byrne - BMC Health Services …, 2013 - Springer
Background A 50 cent prescription levy was introduced in 2010 on the General Medical
Services (GMS) scheme (Irish public health insurance). This study sought to examine patient …